{"id":19116,"date":"2012-02-03T12:10:39","date_gmt":"2012-02-03T17:10:39","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=19116"},"modified":"2012-02-03T12:29:32","modified_gmt":"2012-02-03T17:29:32","slug":"i-dont-understand","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2012\/02\/03\/i-dont-understand\/","title":{"rendered":"for real&#8230;"},"content":{"rendered":"\n<p align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"350\" height=\"285\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/rush-1.gif\" \/><\/p>\n<div align=\"justify\">Among the stories that have emerged over the last twenty years in this age of psychopharmacology, few are as strange as the story of John Rush who was in the Department of Psychiatry at the University of Texas Southwestern for thirty years. Early on, he had studied Cognitive Behavior Therapy with Aaron Beck but not long after arriving at UT, he became a researcher in Depression focusing on psychopharmacology. He was successful in getting NIMH grants as well as industry funding and held various research positions in the Department. Somewhere around 1995, UT and TDMHMR, the State Mental Health Agency, decided to team up in what would become the <strong><font color=\"#200020\">TMAP<\/font><\/strong> program. In the recent Janssen Trial, <a href=\"http:\/\/1boringoldman.com\/texas-transcripts\/2012-01-11%20State%20v.%20Janssen%20Vol%203.pdf#page=108\" target=\"_blank\"><u><strong><font color=\"#200020\">Dr. Shon<\/font><\/strong><\/u><\/a> Medical Director of TDMHMR described it this way:<\/div>\n<ul>\n<div align=\"justify\"><sup>Q. Okay. So this &#8212; this notion of the &#8212; the cooperation and working  together &#8212; between the research universities and the public sector?<br \/>                 A. That&#8217;s correct.<br \/>                 Q. What did that lead to?<br \/>                  A. And that had been going on, but this was my first kind of injection  into dealing with that part of the department. So I went up to the  Department of Psychiatry in Dallas, UT Southwestern, and met with Ken  Altschuler and John Rush, who were the two people who &#8211; Ken Altschuler  was the chair of the department at the time and John Rush a researcher  there. And we met one afternoon and talked about what kind of projects  we might focus on, because one cycle of the projects had come to an end  and we were ready to start another cycle. So we kind of narrowed it down  to a couple of areas. One was psychosocial interventions and the other  was medication interventions. And it was out of that meeting that the  decision was made to focus on improving the quality of medication  prescribing. And that was one of the things that we had talked about  because one of the things that I had seen as medical director in  reviewing prescribing in our state, and it was really not different in  California, was that prescribing could be fairly erratic. It was not  consistent at all. One of the examples I would give as I gave talks is  that if you had six people who had the same symptoms, everything was the  same, perhaps they were clones and had the same psychiatric disorder,  and they walked into six psychiatrists&#8217; offices all lined up, chances  were fairly high that they would walk out with six different medication  programs.<br \/>                 Q. So this &#8212; this issue of the erratic or inconsistent  prescribing of medications for mental illness, that&#8217;s &#8212; that&#8217;s the &#8212;  that&#8217;s one of the topics that you discussed at this meeting at UT  Southwestern?<br \/>                 A. Yes.<br \/>                 Q. And that was in what year?<br \/>                 A. At that meeting in &#8217;95, &#8217;96&#8230;<\/sup><\/div>\n<\/ul>\n<div align=\"justify\">However it came to be, Dr. Rush became TMAP Director and was in charge of starting and running the program. This from the deposition of <a href=\"http:\/\/1boringoldman.com\/texas-transcripts\/2012-01-12%20State%20v.%20Janssen%20Vol%204.pdf#page=10\" target=\"_blank\"><u><strong><font color=\"#200020\">Nancy Burch-Smith<\/font><\/strong><\/u><\/a>, a Janssen employee in charge of disbursing grants:<\/div>\n<ul>\n<div align=\"justify\"><sup>&#8230;When requested, we at times would fund Dr. Shon to share his &#8211; his novel concept of TMAP with other states.<br \/>                   Q. And you say his novel concept?<br \/>                   A. I see him as the conductor or creator, main developer of TMAP.<br \/>                  &#8230;<br \/>                   Q. What do you recall your initial support being?<br \/>                   A. My recollection was that Dr. Rush said that he was approaching every company I believe for the amount of $75,000.<br \/>                    Q. Well, you knew from Janssen&#8217;s perspective that what Janssen was  hoping to get from the support of TMAP was favorable Risperdal  positioning within the TMAP algorithm; isn&#8217;t that right?<br \/>                   A. I  think ultimately we supported TMAP because we totally believed in what  TMAP stood for. Where &#8212; when we agreed to the $75,000, we had no idea  where Risperdal or any of the atypicals would end up on the algorithm.  But, again, it would only be natural &#8211; I work for a for-profit company,  that it would be natural that if we had favorable positioning, it would  ultimately help sales. But that was not our primary objective in  looking at TMAP&#8230;<\/sup>     <\/div>\n<\/ul>\n<div align=\"justify\">But there&#8217;s little question that Dr. Rush was involved with Janssen&#8217;s marketing efforts in the earliest days of TMAP&#8217;s implementation. This is from EKS, the group that developed the TriUniversity Schizophrenia guidelines that were incorporated into TMAP, in a <u><strong><a target=\"_blank\" href=\"http:\/\/media2.kxan.com\/PDF\/Daniel_Rothman_Expert_Report_300dpi.pdf#page=16\"><font color=\"#200020\">1996 note<\/font><\/a><\/strong><\/u> to Janssen:   <\/div>\n<div align=\"justify\">\n<ul>\n<div><sup>&quot;EKS is now ready to move forward in a strategic partnership with Janssen.&quot; The strategy will allow Janssen to &quot;Influence state governments and providers&#8230; Build brand loyalty and commitment with large groups of key providers around the country.&quot; EKS also promised &quot;rapid implementation,&quot; with particular attention to having an impact on Texas decision making. &quot;It is our intent to work with the State of Texas immediately in implementing this product in a select number of CMHC&#8217;s <strong><font color=\"#990000\">with the assistance of A. John Rush, MD<\/font><\/strong>&quot;&#8230; In its summary of the document, EKS wrote: &quot;Your investment in the development of state of the art practice guidelines for schizophrenia is already beginning to pay off in terms of positive exposure in the Texas implementation project.&quot;<br \/>  <\/sup><\/div>\n<\/ul><\/div>\n<div align=\"justify\"><img decoding=\"async\" align=\"right\" width=\"180\" hspace=\"4\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/rush-2.gif\" \/>So Dr. Rush directed the TMAP program, a Depression researcher more involved with the depression algorithm with UT colleague, Dr. Madhukar Trivedi, than the Schizophrenia Algorithm itself [the focus of the Janssen Trial]. Presumably bolstered by his work with the TMAP Algorithms, in 1999 he received an NIMH grant to do the largest clinical trial of a sequenced treatment algorithm for Depression ever done, known as <strong><font color=\"#200020\">STAR*D<\/font><\/strong>, with Dr. Trivedi as his assistant P.I. [<a href=\"http:\/\/1boringoldman.com\/index.php\/2011\/04\/03\/a-thirty-five-million-dollar-misunderstanding\" target=\"_blank\"><strong><u><font color=\"#200020\">a thirty-five million dollar misunderstanding&hellip;<\/font><\/u><\/strong><\/a>]. As you can see in the opening graph, Dr. Rush&#8217;s publication rate soared during the period of TMAP and STAR*D [including his developing a rating scale (QIDS) specifically for this study].           <\/div>\n<p align=\"justify\">But then things took a downward turn. Allen Jones filed his lawsuit alleging that Janssen had misbehaved badly in its involvement with TMAP and the State of Texas joined the suit. TMAP itself began to dissemble. The papers generated by STAR*D continued to flow, but the definitive results were not forthcoming. When they were finally published, they were, candidly, a garbled mess. Rush&#8217;s QIDS was used rather than the expected primary outcome variables, HAM-D. And while derivative STAR*D papers keep coming, the core findings remain unknown to this day. Rush&#8217;s fortune took a further downturn when he was listed by Senator Grassley as one of the psychiatric Key Opinion Leaders with unreported industry income. That year, he left UT and moved to the Duke medical graduate program in Singapore. A later study of his, CO-MED, using multiple antidepressants was a bust &#8211; no improvement. TMAP is now a largely forgotten program &#8211; except in litigation circles. And the results of STAR*D are still essentially unknown &#8211; a $35 M study that produced its own library of articles, but made no contribution to science that I&#8217;m aware of.<\/p>\n<div align=\"justify\">Now, Dr. Ed Pigott, a psychologist who has spent several years studying the deficiencies in STAR*D has filed a whistleblower suit accusing Dr. Rush of having had an inappropriate financial relationship with Forest Laboratories, the maker of Celexa, the first order antidepressant used in STAR*D [<u><strong><a href=\"http:\/\/1boringoldman.com\/index.php\/2012\/02\/02\/19098\/\" target=\"_blank\"><font color=\"#200020\">let the discovery begin&hellip;<\/font><\/a><\/strong><\/u>]. Having spent some time looking at STAR*D myself, I can only agree with each of Dr. Pigott&#8217;s points about the study itself [<a target=\"_blank\" href=\"http:\/\/op.bna.com\/hl.nsf\/id\/jaqo-8qvqcd\/$File\/U.S.%20v.%20Forrest.pdf\"><u><strong><font color=\"#200020\">the suit<\/font><\/strong><\/u><\/a>]. I found it baffling. And then there&#8217;s this &#8211; the COI declarations from the definitive report of the results &#8211; a rogues gallery of KOLs [including the boss of the DSM-5 Task Force]:<\/div>\n<ul><sup><\/p>\n<div align=\"justify\"><u>Dr. Rush<\/u> has served as an advisor,  consultant, or speaker for or received research support from Advanced  Neuromodulation Systems, Inc.; Best Practice Project Management, Inc.;  Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly &amp; Company;  <strong><font color=\"#990000\">Forest Pharmaceuticals, Inc.<\/font><\/strong>; Gerson Lehman Group; GlaxoSmithKline;  Healthcare Technology Systems, Inc.; Jazz Pharmaceuticals; Merck &amp;  Co., Inc.; the National Institute of Mental Health; Neuronetics; Ono  Pharmaceutical; Organon USA Inc.; Personality Disorder Research Corp.;  Pfizer Inc.; the Robert Wood Johnson Foundation; the Stanley Medical  Research Institute; the Urban Institute; and Wyeth-Ayerst Laboratories  Inc. He has equity holdings in Pfizer Inc and receives royalty\/patent  income from Guilford Publications and Healthcare Technology Systems,  Inc.<\/div>\n<div align=\"justify\"><u>Dr. Trivedi<\/u> has served as an advisor,  consultant, or speaker for or received research support from Abbott  Laboratories, Inc.; Akzo (Organon Pharmaceuticals Inc.); Bayer;  Bristol-Myers Squibb Company; Cephalon, Inc.; Corcept Therapeutics,  Inc.; Cyberonics, Inc.; Eli Lilly &amp; Company; <strong><font color=\"#990000\">Forest Pharmaceuticals;<\/font><\/strong>  GlaxoSmithKline; Janssen Pharmaceutica; Johnson &amp; Johnson PRD;  Meade Johnson; the National Institute of Mental Health; the National  Alliance for Research in Schizophrenia and Depression; Novartis;  Parke-Davis Pharmaceuticals, Inc.; Pfizer Inc; Pharmacia &amp; Upjohn;  Predix Pharmaceuticals; Sepracor; Solvay Pharmaceuticals, Inc.; and  Wyeth-Ayerst Laboratories.<\/div>\n<div align=\"justify\"><u>Dr. Wisniewski<\/u> has received research support  from the National Institute of Mental Health and served as an  advisor\/consultant for Cyberonics, Inc.<\/div>\n<div align=\"justify\"><u>Dr. Nierenberg<\/u> has served as an advisor,  consultant, or speaker for or received research support from  Bristol-Myers Squibb Company; Cederroth; Cyberonics, Inc.; Eli Lilly  &amp; Company; <strong><font color=\"#990000\">Forest Pharmaceuticals Inc.;<\/font><\/strong> Genaissance;  GlaxoSmithKline; Innapharma; Janssen Pharmaceutica; Lichtwer Pharma; the  National Institute of Mental Health; the National Alliance for Research  in Schizophrenia and Depression; Neuronetics; Organon, Inc.; Pfizer  Inc; Sepracor; Shire; Stanley Foundation; and Wyeth-Ayerst Laboratories.        <\/div>\n<div align=\"justify\"><u>Dr. Stewart<\/u> has served as an advisor,  consultant, or speaker for or received research support from Eli Lilly  &amp; Company; GlaxoSmithKline; Organon USA Inc.; Shire; and Somerset.<\/div>\n<div align=\"justify\"><u>Dr. Warden<\/u> has received research support  from the National Institute of Mental Health and has equity holdings in  Bristol-Myers Squibb Company and Pfizer, Inc.<\/div>\n<div align=\"justify\"><u>Dr. Thase<\/u> has served as an advisor,  consultant, or speaker for AstraZeneca; Bristol-Myers Squibb Company;  Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly &amp; Company; <strong><font color=\"#990000\">Forest  Laboratories, Inc.;<\/font><\/strong> GlaxoSmithKline; Janssen Pharmaceutica; Eli Lilly  &amp; Company; Novartis; Organon, Inc.; Pfizer Pharmaceutical; Sanofi  Aventis; Sepracor, Inc.; Shire US Inc.; and Wyeth Pharmaceuticals.<\/div>\n<div align=\"justify\"><u>Dr. Lavori<\/u> has served as an advisor,  consultant, or speaker for or received research support from  Bristol-Myers Squibb Company; Celera Diagnostics Inc; Cyberonics, Inc.;  the Department of Veterans Affairs; <strong><font color=\"#990000\">Forest Pharmaceuticals, Inc.;<\/font><\/strong>  Glaxo-SmithKline; Leaf Cabrezer Hyman and Bernstein; the National  Institutes of Health; and Neuronetics, Inc. <\/div>\n<div align=\"justify\"><u>Dr. McGrath<\/u> has served as an advisor,  consultant, or speaker for or received research support from Eli Lilly  &amp; Company; GlaxoSmithKline; Lipha Pharmaceuticals; the National  Institute of Mental Health; the National Institute on Alcohol Abuse and  Alcoholism; New York State Department of Mental Hygiene; Organon, Inc.;  Research Foundation for Mental Hygiene (New York State); and Somerset  Pharmaceuticals. <\/div>\n<div align=\"justify\"><u>Dr. Rosenbaum<\/u> has served as an advisor,  consultant, or speaker for or received research support from  Astra-Zeneca; Boehringer-Ingelheim; Bristol-Myers Squibb Company;  Cephalon; Compellis; Cyberonics; EPIX; <strong><font color=\"#990000\">Forest;<\/font><\/strong> GlaxoSmithKline; Janssen;  Lilly; MedAvante; Neuronetics; Novartis; Orexigen; Organon; Pfizer,  Inc; Roche Diagnostics; Sanofi; Schwartz; Somaxon; Somerset; Sepracor;  Shire; Supernus; and Wyeth. He has equity holdings in Compellis,  Medavante, and Somaxon. <\/div>\n<div align=\"justify\"><u>Dr. Sackeim<\/u> has served as an advisor,  consultant, or speaker for or received research support from Cyberonics,  Inc.; Eli Lilly &amp; Company; Magstim Ltd.; MECTA Corporation;  Neurocrine Biosciences Inc.; Neuronetics Inc.; NeuroPace Inc.; and  Pfizer Inc. <\/div>\n<div align=\"justify\"><u>Dr. Kupfer<\/u> has served as an advisor,  consultant, or speaker for or received research support from Amersham;  the Commonwealth of Pennsylvania; Corcept Corporated; Eli Lilly &amp;  Company; F. Hoffmann-La Roche Ltd.; <strong><font color=\"#990000\">Forest Pharmaceuticals; <\/font><\/strong>Lundbeck;  the National Institute of Mental Health; Novartis; Pfizer, Inc; Servier  Amerique; and Solvay\/Wyeth. He has equity holdings in Body Media and Med Avante and receives royalty income from Oxford University Press. <\/div>\n<div align=\"justify\"><u>Dr. Fava<\/u> has served as an advisor,  consultant, or speaker for or received research support from Abbott  Laboratories; Alkermes; Aspect Medical Systems; Astra-Zeneca; Bayer AG;  Biovail Pharmaceuticals, Inc.; BrainCells, Inc.; Bristol-Myers Squibb  Company; Cephalon; Compellis; Cypress Pharmaceuticals; Dov  Pharmaceuticals; Eli Lilly &amp; Company; EPIX Pharmaceuticals;  Fabre-Kramer Pharmaceuticals, Inc.; <strong><font color=\"#990000\">Forest Pharmaceuticals Inc.;<\/font><\/strong>  GlaxoSmithKline; Grunenthal GmBH; J &amp; J Pharmaceuticals; Janssen  Pharmaceutica; Jazz Pharmaceuticals; Knoll Pharmaceutical Company;  Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck; MedAvante, Inc.;  Novartis; Nutrition 21; Organon Inc.; PamLab, LLC; Pfizer, Inc;  PharmaStar; Pharmavite; Roche; Sanofi\/Synthelabo; Sepracor; Solvay  Pharmaceuticals, Inc.; Somerset Pharmaceuticals; and Wyeth-Ayerst  Laboratories. He has equity holdings in Compellis and MedAvante. <\/div>\n<div align=\"justify\"><u>Dr. Niederehe<\/u>, <u>Dr. Lebowitz<\/u>, and <u>Mr. Luther<\/u> report no competing interests.<\/div>\n<p><\/sup><\/ul>\n<div align=\"justify\">The outcome report of STAR*D [<strong><a href=\"http:\/\/ajp.psychiatryonline.org\/cgi\/content\/abstract\/163\/11\/1905\" target=\"_blank\"><font color=\"#200020\">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report<\/font><\/a><\/strong>] begins:<\/div>\n<ul>\n<div align=\"justify\"><sup>Symptom remission is the desired goal of  treatment for depression, given its implications for better daily  functioning and better longer-term prognosis. Since no treatment is a  panacea, several sequential treatment steps are often needed to obtain  remission with a tolerated treatment. If a trial does not result in  remission, it is an unsuccessful trial, whether due to lack of efficacy  or intolerable side effects, as long as the treatment is vigorously  dosed to tolerance and provided for a sufficient duration to achieve  remission. The number of treatment steps needed to achieve an adequate  benefit is typically used to gauge the degree of treatment resistance,  usually with a focus on acute outcomes without reference to longer-term  outcomes.<\/sup><\/div>\n<\/ul>\n<div align=\"justify\">And concludes:<\/div>\n<ul>\n<div align=\"justify\"><sup>After two treatment steps, it appears that  over 50% of patients will achieve remission if they stay in treatment  (i.e., 36.8% step 1 plus 30.6% of the remaining 63.2% of patients).  Thereafter, the chances of subsequent remission  are much lower. The  theoretical cumulative remission rate after four acute treatment steps  was 67%.<\/sup><\/div>\n<\/ul>\n<div align=\"justify\">  As I scroll through Dr. Rush&#8217;s 109 page CV &#8211; over 500 articles, more than 600 meeting presentations, numerous honors, awards, grants, book chapters, speeches, etc. &#8211; I&#8217;m wondering how it all came down to directing the corrupt TMAP program and submitting this <strong><font color=\"#200020\">indefensible conclusion<\/font><\/strong> to his STAR*D study &#8211; a study now sitting under the cloud of corruption. I also wonder why the NIMH who funded STAR*D hasn&#8217;t insisted that Dr. Rush et al publish the actual outcome data from the study or even evaluated the results themselves. I&#8217;m embarrassed that a watchdog has had to come from outside psychiatry, rather than from within our own ranks [though I&#8217;m glad it finally came from somewhere].&nbsp;<\/div>\n<p align=\"justify\">Dr. Rush and I are within a year in age, and our careers roughly paralleled up until the time when the DSM-III was published and psychiatry changed so dramatically. As much as I&#8217;d like to demonize him for falling in with the whole PHARMA-driven deterioration of academic medicine and his participation in shady enterprises like TMAP and STAR*D, I still find myself wondering about his journey through the last twenty-five years in the main stream of modern psychiatry. What the hell happened? He followed every lead along the road of depression research &#8211; Cognitive Behavior Therapy, most of the Drugs, the DST and other neurochemistry, the VNS system, ECT, etc, etc. He worked and published with most of the luminaries in the world of academic psychiatry over his career. But what was the point of amassing all of those publications, presentations, etc? How did he end up administering a Public Health program like TMAP that was little more than a tawdry PHARMA scam? Or squeezing that stream of extra articles out of the STAR*D study without ever addressing what the study was about in the first place? Or abruptly heading for Singapore at the end of a thirty year career in Texas when he should&#8217;ve been getting a watch at a retirement party? Why did he sign on to the <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21208417\" target=\"_blank\"><u><strong><font color=\"#200020\">iSPOT<\/font><\/strong><\/u><\/a> study with the likes of Nemeroff and Schlatzberg, chasing the next depression research dead end?  <\/p>\n<div align=\"justify\">Sometimes when people say, &quot;I don&#8217;t understand,&quot; it&#8217;s code for &quot;I don&#8217;t approve.&quot; Well I obviously don&#8217;t approve, but also &quot;I don&#8217;t understand&quot; &#8211; for real&#8230;<\/div>\n<hr size=\"1\" \/>\n<div align=\"justify\">[see also <u><strong><a href=\"http:\/\/www.pharmalot.com\/2012\/02\/was-nimh-trial-rigged-to-favor-a-forest-drug\/\" target=\"_blank\"><font color=\"#200020\">Was NIMH Trial Rigged To Favor A Forest Drug?<\/font><\/a><\/strong><\/u>]<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Among the stories that have emerged over the last twenty years in this age of psychopharmacology, few are as strange as the story of John Rush who was in the Department of Psychiatry at the University of Texas Southwestern for thirty years. Early on, he had studied Cognitive Behavior Therapy with Aaron Beck but not [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-19116","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/19116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=19116"}],"version-history":[{"count":31,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/19116\/revisions"}],"predecessor-version":[{"id":40085,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/19116\/revisions\/40085"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=19116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=19116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=19116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}